Press release
PCSK9 Inhibitor Pipeline Insights Report 2024
PCSK9 Inhibitor Pipeline
In the PCSK9 Inhibitor Pipeline Report, a detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, PCSK9 Inhibitor NDA approvals (if any), and product development activities comprising the technology, PCSK9 Inhibitor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the PCSK9 Inhibitor Pipeline treatment landscape of the report, click here @ PCSK9 Inhibitor Pipeline Outlook- https://www.delveinsight.com/report-store/proprotein-convertase-subtilisin-kexin-type-9-pcsk9-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the PCSK9 Inhibitor Pipeline Report
• DelveInsight's PCSK9 Inhibitor Pipeline analysis depicts a robust space with 14+ active players working to develop 14+ pipeline treatment therapies.
• The leading companies are working in the PCSK9 Inhibitor market include Ionis Pharmaceuticals, Akeso Biopharma, Amgen, Novo Nordisk, Civi BioPharma, and others.
• Promising PCSK9 Inhibitor Pipeline Therapies in the various stages of development include AK102, Statins, Ezetimibe, MK-0616, Bempedoic Acid 180 mg, Evolocumab, IBI306, and others.
• On March 2023, LIB Therapeutics LLC announced a study of phase 3 clinical trials for lerodalcibep. The study is to assess the long-term safety, tolerability, and efficacy after 48 and 72 weeks with monthly (Q4W [
• On July 2023, Brigham and Women's Hospital announced a study of phase 4 clinical trials for Evolocumab and Statins (Cardiovascular Agents). The study would involve a total of 120 patients across 3 different hospitals in Boston, Massachusetts.
PCSK9 Inhibitor Overview
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) is a serine protease involved in cholesterol homeostasis. After binding to the complex low-density lipoprotein (LDL)-receptor, PCSK9 induces its intracellular degradation, thus reducing serum LDL clearance.
For further information, refer to the detailed PCSK9 Inhibitor Unmet Needs, click here for PCSK9 Inhibitor Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/proprotein-convertase-subtilisin-kexin-type-9-pcsk9-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
PCSK9 Inhibitor Emerging Drugs Profile
• Evolocumab: Amgen
Evolocumab (Repatha) is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). It is being investigated for the treatment of patients with high-risk cardiovascular disease without prior heart attack or stroke. It is being investigated for the treatment of familial hypercholesterolemia in pediatric patients.
• ION449: Ionis Pharmaceuticals
ION449 (formerly IONIS-AZ4-2.5-LRx), also known as AZD8233, is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is integrally involved in the regulation of LDL-cholesterol. Genetic studies have shown that individuals with life-long reduction of LDL-C due to reduced function of PCSK9 have substantially reduced risk of cardiovascular disease. Pharmacological inhibition of PCSK9 substantially lowers LDL-C. ION449 is designed to reduce the liver production of PCSK9 and lower the plasma level of LDL-C and thus reduce the risk of cardiovascular disease.
PCSK9 Inhibitor Therapeutics Assessment
There are approx. 14+ key companies which are developing the therapies for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor. The PCSK9 Inhibitor companies which have their Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Amgen.
Request a sample and discover the recent advances in PCSK9 Inhibitor Ongoing Clinical Trial Analysis and Medications, Click here for more details @ PCSK9 Inhibitor Segmentation- https://www.delveinsight.com/sample-request/proprotein-convertase-subtilisin-kexin-type-9-pcsk9-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
PCSK9 Inhibitor Drugs and Companies
• AK102: Akeso
• Statins: AD Pharmaceuticals Co. Ltd
• MK-0616: Merck Sharp & Dohme LLC
PCSK9 Inhibitor Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the PCSK9 Inhibitor Therapeutics Market include-
Ionis Pharmaceuticals, Akeso Biopharma, Amgen, Novo Nordisk, Civi BioPharma, and others.
Dive deep into rich insights for drugs for PCSK9 Inhibitor Pipeline, click here @ PCSK9 Inhibitor Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/proprotein-convertase-subtilisin-kexin-type-9-pcsk9-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the PCSK9 Inhibitor Pipeline Report
• Coverage- Global
• Companies- Ionis Pharmaceuticals, Akeso Biopharma, Amgen, Novo Nordisk, Civi BioPharma, and others.
• Therapies- AK102, Statins, Ezetimibe, MK-0616, Bempedoic Acid 180 mg, Evolocumab, IBI306, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on PCSK9 Inhibitor Merger and acquisitions, Licensing Activities- https://www.delveinsight.com/sample-request/proprotein-convertase-subtilisin-kexin-type-9-pcsk9-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Evolocumab: Amgen
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. ION449: Ionis Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. Drug Name: Company Name
14. Drug profiles in the detailed report…..
15. Preclinical stage products
16. Oral PCSK9 inhibitor: Esperion Therapeutics
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Key Companies
20. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Key Products
21. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor- Unmet Needs
22. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor- Market Drivers and Barriers
23. Appendix
List of Important Links-
https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market
https://www.delveinsight.com/report-store/glaucoma-market
https://www.delveinsight.com/report-store/uveitis-market
https://www.delveinsight.com/report-store/hemophilia-a2030-market
https://www.delveinsight.com/report-store/nephrotic-syndrome-market
https://www.delveinsight.com/report-store/short-bowel-syndrome-market
https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-market
https://www.delveinsight.com/report-store/retinitis-pigmentosa-market
https://www.delveinsight.com/report-store/aplastic-anemia-market
https://www.delveinsight.com/report-store/cystic-fibrosis-market
https://www.delveinsight.com/report-store/heart-failure-market
https://www.delveinsight.com/report-store/peanut-allergy-market
https://www.delveinsight.com/report-store/smoking-cessation-market
https://www.delveinsight.com/report-store/post-operative-pain-management-market
https://www.delveinsight.com/report-store/obstructive-sleep-apnea-osa-market
https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release PCSK9 Inhibitor Pipeline Insights Report 2024 here
News-ID: 3406027 • Views: …
More Releases from DelveInsight Business Research LLP
RNA Interference Pipeline Drugs Insights Report 2025: Clinical Trial Studies, EM …
DelveInsight's "RNA Interference Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 90+ pipeline drugs in the RNA Interference pipeline landscape. It covers the RNA Interference pipeline drug profiles, including clinical and nonclinical stage products. It also covers the RNA Interference therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment…
Amyotrophic Lateral Sclerosis Pipeline Drugs Insights Report 2025: Clinical Tria …
DelveInsight's, "Amyotrophic Lateral Sclerosis Pipeline Insight 2025" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis pipeline landscape. It covers the Amyotrophic Lateral Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Amyotrophic…
NK Cell Therapy Pipeline Outlook Report 2025: Clinical Trial Studies, EMA, PDMA, …
DelveInsight's, "NK Cell Therapies Pipeline Insight, 2025" report provides comprehensive insights about 140+ companies and 160+ pipeline drugs in NK Cell Therapies pipeline landscape. It covers the NK Cell Therapies pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NK Cell Therapies pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the…
TCR Therapy Pipeline Drugs Insights Report 2025: Clinical Trials, EMA, PDMA, FDA …
DelveInsight's "TCR Therapy Pipeline Insight 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the TCR Therapy pipeline landscape. It covers the TCR Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the TCR Therapy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment…
More Releases for PCSK9
United States PCSK9 Inhibitor Market 2025 | Growth Drivers, Competitive Landscap …
Market Size and Growth
PCSK9 Inhibitor Market reached US$ 1.96 Billion in 2024 and is expected to reach US$ 7.67 Billion by 2033, growing at a CAGR of 16.5% during the forecast period 2025-2033.
Key Development:
United States: Recent Industry Developments
✅ In September 2025, Merck's investigational oral PCSK9 inhibitor, Enlicitide Decanoate, achieved all primary and key secondary endpoints in the pivotal CORALreef Lipids study, demonstrating significant LDL-C reduction compared to placebo.
✅ In March…
PCSK9 Inhibitors Market Growth, Applications, Innovations and Business Outlook b …
Introduction
Cardiovascular diseases remain the leading cause of mortality worldwide, with elevated low-density lipoprotein cholesterol (LDL-C) being one of the most significant risk factors. While statins have long been the cornerstone of lipid-lowering therapy, many patients experience inadequate response or intolerance. This has driven the emergence of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors as a breakthrough class of drugs, offering dramatic LDL-C reductions and improved cardiovascular outcomes.
PCSK9 inhibitors work by…
PCSK9 Inhibitors Market Poised for Significant Growth by 2034, Predicts DelveIns …
The PCSK9 Inhibitors market is steadily advancing, driven by evolving treatment strategies and ongoing research. DelveInsight's latest 7MM report offers in-depth insights into key epidemiology trends and market dynamics.
DelveInsight's "PCSK9 Inhibitors - Market Insight, Epidemiology, And Market Forecast - 2034 [https://www.delveinsight.com/report-store/pcsk9-inhibitors-psck9i-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr] report offers an in-depth understanding of the PCSK9 Inhibitors, historical and forecasted epidemiology as well as the PCSK9 Inhibitors market trends in the United States, EU5 (Germany, Spain, Italy,…
PCSK9 inhibitors Market Trends Unraveled: Insights, Players, and Future Projecti …
"Pcsk9 Inhibitors Market Accounted For US$ X.X Billion In 2020 And Is Estimated To Be US$ X.X Billion By 2030 And Is Anticipated To Register A Cagr Of X.X% .".
With thorough company profiles, recent developments, and other information, the PCSK9 inhibitors Market Report provides an in-depth analysis of major trends, motivating reasons, obstacles, segmentation, regulatory policies, and important players. The PCSK9 inhibitors Market Report offers a thorough synopsis of the…
PCSK9 Inhibitor Market Size, Share, Economic Growth, Emerging Trends and Forecas …
PCSK9 Inhibitor Market 2021 by Technology, Manufacturers, Regions, Type, and Application, Forecast guide to light the excellent analysis on the market synopsis. The report offers a primary focus on important factors in the global PCSK9 Inhibitor industry. The report includes perceptive information about gross revenue, cost, value, capacity, pricing, and profit margins concerning historical analysis and forecast estimation for the 2021 to 2031 time period. It presents a close overview…
PCSK9 Inhibitors Market Size was approximately USD 1,309 million in 2021
PCSK9i market is expected to grow significantly owing to the use of PCSK9 inhibitors in statin-intolerant patients, promising future strategies of PCSK9 inhibition, implications of PCSK9 inhibitors in broader therapy areas, and PCSK9 inhibition in a prophylactic setting, which can relieve the CVD burden and also the key pharmaceuticals like AstraZeneca, Ionis Pharmaceuticals, CiVi Biopharma, LIB Therapeutics, Merck Sharp & Dohme, Sanofi, Regeneron Pharmaceuticals, Amgen, Novartis, Alnylam Pharmaceuticals Therapeutics are…
